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Introduction and Objective
•

•

•

•

Mafenide acetate is an antibiotic used to prevent and treat
skin infections, specifically pseudomonas, for some
patients with burns. Mafenide acetate does not prevent or
treat fungal infections therefore antifungal medications are
commonly added.
Purpose: The Journal of burn care & research found in 2017
that 2.5% mafenide acetate is equally effective compared
to 5% mafenide acetate.1 Based on these findings, Lehigh
Valley Health Network’s (LVHN) Regional Burn Center
transitioned from 5% to 2.5% mafenide acetate.
Our first objective was to establish baseline data for
patients treated with 2.5% mafenide acetate between the
dates of August 2015 to April 2021.
Our second objective was to identify if during the COVID-19
pandemic infection rates rose in the patient population
treated with mafenide acetate, as personal protective
equipment (PPE) was spared for COVID-19 patients.

Methods
Quality improvement project that
includes a chart review of 317
patients from August 2015 to April
2021
COVID-19 chart review of 78
patients from March 16, 2020, to
May 19, 2021

Resources consisted of the
electronic medical record
(EMR), RedCAP, Microsoft
excel, pharmacy and infection
control databases

Mafenide
acetate data
Information gathered
included how many doses of
mafenide acetate were given,
sites where mafenide acetate
was placed and what
infections the patient
acquired

Descriptive statistics were
used to collect demographic
information such as gender,
race, ethnicity, age,
comorbidities, length of stay
(LOS) and total burn surface
area (TBSA)
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Figure 1. Comorbidities and age were higher during COVID-19mafenide. TBSA was higher before COVID-19-mafenide.
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Figure 2.
Males were
the higher
gender for
both time
frames. In
total 12
deaths were
calculated.
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•

As for doses of mafenide administered, patients who had a
longer LOS received more doses in both groups.

•

Comorbidities did not significantly contribute to the LOS in
either group.

•

Patients who had a higher number of positive cultures had a
longer LOS in both mafenide groups.

•

Figure 4 shows that culture counts were higher before
COVID-19- mafenide. We suspect this is because the average
TBSA was higher for that time frame. The figure also shows
that culture counts were higher during COVID-19-all
inpatient burn patients. We suspect this is due to the lack of
PPE during that time frame.

•

Figure 5 shows that there was no statistically significant
difference between positive culture counts before COVID-19mafenide compared to during COVID-19-mafenide.
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Figure 4.
Culture counts were higher before
COVID-19-mafenide.
Culture counts were higher during
COVID-19- all inpatient burn patients.
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During the PPE sparing time frame, we found that older
patients had a longer LOS. We suspect that the lack of
availability in nursing homes during COVID-19 caused this.
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Figure 3. Doses of mafenide
were higher before COVID-19mafenide.
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Discussion and future directions
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Figure 5. There
are no
statistically
significant
differences in
the following
categories
when
comparing
mafenide data.
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If the exact date of
change from 5% to
2.5% mafenide acetate
becomes available, it
would be beneficial to
look further into
infection rates for
comparison.

Continuous observation
of infection rates is
recommended as this
project provides a
baseline for
comparison.
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